KIR ligand C2 is associated with increased susceptibility to childhood ALL and confers an elevated risk for late relapse

Blood. 2014 Oct 2;124(14):2248-51. doi: 10.1182/blood-2014-05-572065. Epub 2014 Aug 27.

Abstract

A role for HLA class I polymorphism in childhood acute lymphoblastic leukemia (ALL) has been suggested for many years, but unambiguous associations have not been found. Here, we show that the HLA-C-encoded supertypic epitope C2, which constitutes a high-affinity ligand for the inhibitory natural killer (NK) cell receptor KIR2DL1, is significantly increased in ALL patients (n = 320; P = .005). Stratification for ethnicity and disease subtype revealed a strong association of C2 with B-ALL in German cases (P = .0004). The effect was independent of KIR2DS1 and KIR2DL1 allelic polymorphism and copy number. Analysis of clinical outcome revealed a higher incidence of late relapse (> 2.5 years) with increasing number of C2 alleles (P = .014). Our data establish C2 as novel risk factor and homozygosity for C1 as protective for childhood B-ALL supporting a model in which NK cells are involved in immunosurveillance of pediatric B-ALL via interaction of KIR with HLA-C ligands.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Child
  • Child, Preschool
  • Cohort Studies
  • Epitopes / chemistry
  • Female
  • Genetic Predisposition to Disease*
  • Genotype
  • Germany
  • HLA-C Antigens / metabolism
  • Homozygote
  • Humans
  • Infant
  • Killer Cells, Natural / cytology
  • Ligands
  • Male
  • Multivariate Analysis
  • Neoplasm Recurrence, Local / genetics
  • Polymorphism, Genetic
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Receptors, KIR2DL1 / metabolism*
  • Recurrence
  • Risk Factors
  • Treatment Outcome

Substances

  • Epitopes
  • HLA-C Antigens
  • KIR2DL1 protein, human
  • Ligands
  • Receptors, KIR2DL1